<DOC>
	<DOCNO>NCT01848990</DOCNO>
	<brief_summary>The primary objective study compare difference glycosylated hemoglobin ( HbA1c ) baseline Month 6 use Hylenex recombinant preadministration continuous subcutaneous insulin infusion ( CSII ) versus standard CSII evaluate safety Hylenex recombinant preadministration , include local tolerability , adverse event , hypo- hyperglycemia rate .</brief_summary>
	<brief_title>CONSISTENT 1 : Metabolic Safety Outcomes Hylenex Recombinant ( Hyaluronidase Human Injection ) Preadministered CSII Infusion Site Participants With Type 1 Diabetes Mellitus ( T1DM )</brief_title>
	<detailed_description>This Phase 4 study design demonstrate noninferiority pretreatment Hylenex recombinant CSII set rapid-acting analog insulin alone respect glycemic control assess change HbA1c participant Type 1 diabetes mellitus . Total duration study treatment 24 month . However , accord study design , primary outcome measure assess 6 month interim analysis complete 6 month secondary outcome measure adverse event . Therefore , data report clinical trial record 6-month interim analysis .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>1 . Male female age 18 year old history T1DM least 12 month 2 . Glycosylated hemoglobin ( HbA1c ) 6.5 % 9.5 % ( inclusive ) base central laboratory result 3 . Fasting Cpeptide &lt; 0.6 nanogram per milliliter ( ng/mL ) 4 . Current use insulin pump compatible available tube Hylenex recombinant infusion use infusion set compatible tube available willingness switch infusion set compatible tube available infusion Hylenex recombinant 5 . Current treatment time screen insulin &lt; 300 unit per day ( U/day ) 6 . Participants routinely use continuous glucose monitoring ( CGM ) ( define average CGM use 5 day per week precede 3 month ) routinely use CGM eligible inclusion study . Intermittent use CGM also acceptable criterion use stratify randomization . 7 . Participants good general health base medical history physical examination , without medical condition might prevent completion study drug infusion assessment require protocol . 1 . Type 2 diabetes 2 . Known suspected allergy component study drug study 3 . Severe proliferative retinopathy maculopathy , and/or gastroparesis , and/or severe neuropathy , particular autonomic neuropathy , severity impede participant 's ability comply protocol procedure , judge Investigator 4 . History transmural myocardial infarction , congestive heart failure uncontrolled hypertension ( diastolic blood pressure [ BP ] consistently &gt; 100 millimeter mercury [ mmHg ] ) exclusionary 5 . As judged Investigator , clinically significant active disease gastrointestinal , cardiovascular ( include history stroke , history arrhythmia , conduction delay electrocardiogram [ ECG ] ) , hepatic , neurological , renal , genitourinary , pulmonary , hematological system severity impede participant 's ability comply protocol procedures 6 . History illness disease opinion Investigator might confound result study pose additional risk administer study drug participant 7 . As judged Investigator , clinically significant finding routine laboratory data screen 8 . Use drug may interfere interpretation study result know cause clinically relevant interference hyaluronidase action , insulin action , glucose utilization , recovery hypoglycemia ( include systemic pharmacologic corticosteroid ) . Use pramlintide glucagonlike peptide [ GLP ] 1 receptor agonist exclusionary participant use agent subject stratified randomization . Use aspirin ( acetylsalicylic acid [ ASA ] ) 325 milligram ( mg ) /day exclusionary note analysis . 9 . Hypoglycemic unawareness severity impede participant 's ability comply protocol procedure , judge Investigator . 10 . Current addiction alcohol substance abuse determine Investigator . 11 . Pregnancy , breastfeeding , intention become pregnant , use adequate contraceptive measure ( adequate contraceptive measure consist sterilization , intrauterine device [ IUD ] , oral injectable contraceptive , and/or barrier method ) . Abstinence alone consider adequate contraceptive measure purpose study . 12 . Mental incapacity , unwillingness , language barrier preclude adequate understanding cooperation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>Sub Cutaneous Insulin Infusion</keyword>
	<keyword>Rapid Acting Analog Insulin</keyword>
	<keyword>Hylenex</keyword>
	<keyword>Halozyme</keyword>
	<keyword>Phase 4</keyword>
</DOC>